"Although similar research has been conducted elsewhere, this is the first time anybody has manufactured blood to the appropriate quality and safety standards for transfusion into a human being," said Prof Turner. There are plans in place for the trial to be concluded by late 2016 or early 2017, he said.

The technique highlights the prospect of a limitless supply of manufactured type-O blood, free of disease and compatible with all patients.